Revvity, Inc. is a leading provider of health sciences solutions valued at $11.4 billion. Despite slipping 21.7% from its 52-week high, the stock gained 21.3% over the past three months, outperforming competitors. Analysts are bullish on Revvity, with a consensus rating of “Moderate Buy” and a price target of $112.53.

Revvity’s strengths lie in its diversification, scale, and technological capabilities. Although the stock rose 5% in the last six months, it dipped 13.4% in the past 52 weeks. RVTY is trading above its 50-day moving average since October, signaling a bullish trend.

After reporting Q3 results, Revvity’s revenue stood at $7 billion, up 2.2% year over year. Its adjusted EPS fell 7.8% to $1.18 from the year-ago quarter. The stock’s rival, Danaher Corporation, has outperformed Revvity with 10.4% gains on a six-month basis.

Wall Street analysts have a positive outlook on Revvity’s future, with a consensus rating of “Moderate Buy” and a mean price target of $112.53, suggesting a potential upside of 12% from current price levels. Revvity continues to innovate and maintain a competitive edge in the healthcare and diagnostics industry.

Read more at Yahoo Finance: How Is Revvity’s Stock Performance Compared to Other Health Care Stocks?